Equities Analysts Set Expectations for Liquidia Q2 Earnings

Liquidia Co. (NASDAQ:LQDA) – Investment analysts at HC Wainwright issued their Q2 2025 earnings per share estimates for shares of Liquidia in a research note issued to investors on Thursday, March 20th. HC Wainwright analyst A. Fein anticipates that the company will earn ($0.46) per share for the quarter. HC Wainwright has a “Buy” rating and a $29.00 price target on the stock. The consensus estimate for Liquidia’s current full-year earnings is ($1.51) per share. HC Wainwright also issued estimates for Liquidia’s Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.25) EPS and FY2029 earnings at $0.51 EPS.

Liquidia (NASDAQ:LQDA) last announced its earnings results on Wednesday, March 19th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.08). The company had revenue of $2.92 million for the quarter, compared to analysts’ expectations of $4.60 million. Liquidia had a negative net margin of 765.38% and a negative return on equity of 163.21%.

A number of other equities analysts have also recently weighed in on the stock. Needham & Company LLC upped their price objective on shares of Liquidia from $19.00 to $25.00 and gave the company a “buy” rating in a research report on Thursday. Wells Fargo & Company initiated coverage on Liquidia in a research note on Friday, December 20th. They set an “overweight” rating and a $20.00 price objective for the company. Finally, Scotiabank upped their target price on Liquidia from $30.00 to $34.00 and gave the company a “sector outperform” rating in a research report on Thursday. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $26.63.

Liquidia Trading Up 3.5 %

NASDAQ LQDA opened at $15.44 on Friday. The stock has a market cap of $1.31 billion, a P/E ratio of -9.47 and a beta of 0.07. The company’s fifty day simple moving average is $14.73 and its 200-day simple moving average is $12.14. Liquidia has a 52 week low of $8.26 and a 52 week high of $16.99.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. California State Teachers Retirement System boosted its holdings in shares of Liquidia by 17.5% during the fourth quarter. California State Teachers Retirement System now owns 51,928 shares of the company’s stock valued at $611,000 after acquiring an additional 7,725 shares during the period. Toronto Dominion Bank acquired a new position in Liquidia during the 4th quarter valued at about $235,000. Alpine Global Management LLC grew its position in Liquidia by 50.0% in the 4th quarter. Alpine Global Management LLC now owns 150,000 shares of the company’s stock worth $1,764,000 after purchasing an additional 50,000 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in shares of Liquidia by 26.9% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 105,734 shares of the company’s stock valued at $1,243,000 after purchasing an additional 22,445 shares during the period. Finally, Whitefort Capital Management LP raised its holdings in shares of Liquidia by 16.8% during the fourth quarter. Whitefort Capital Management LP now owns 1,987,245 shares of the company’s stock valued at $23,370,000 after buying an additional 285,220 shares during the last quarter. 64.54% of the stock is currently owned by institutional investors.

Insider Activity at Liquidia

In other Liquidia news, CFO Michael Kaseta sold 23,370 shares of the firm’s stock in a transaction dated Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total value of $275,298.60. Following the transaction, the chief financial officer now owns 401,755 shares of the company’s stock, valued at $4,732,673.90. This trade represents a 5.50 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, General Counsel Russell Schundler sold 16,393 shares of the company’s stock in a transaction that occurred on Tuesday, January 14th. The shares were sold at an average price of $11.78, for a total value of $193,109.54. Following the transaction, the general counsel now directly owns 573,478 shares of the company’s stock, valued at $6,755,570.84. This trade represents a 2.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 71,245 shares of company stock valued at $843,326. Corporate insiders own 30.10% of the company’s stock.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).